Leiden University Medical Center account plan
Medical research and training
At a glance
LUMC is the Leiden University Medical Center in the Netherlands, with over 11,000 staff and FY2025 operating revenue of EUR 1,286.3 million.
Leiden University Medical Center (LUMC, legally Academisch Ziekenhuis Leiden) is a Dutch public-law university medical centre combining patient care, research, education and valorisation, and part of the Leiden Bio Science Park. It treats more than 1.3 million patients with complex conditions and had more than 11,000 staff at end-2025 (7,467 average FTE in the consolidated group). FY2025 consolidated operating revenue was EUR 1,286.3 million (2024: EUR 1,200.8 million) and the group result EUR 16.5 million. Income comes mainly from health insurers, state availability contributions and the university contribution. Cardiologist Martin Jan Schalij chairs the Executive Board.
Business units
Patient care
EUR 888.0 million care revenue (about 69% of group operating revenue, computed)High-complexity hospital care paid mainly by health insurers (EUR 689.1 million Health Insurance Act revenue in 2025), plus academic-care availability contributions and youth mental-health care. Less complex care is being moved to regional partners, with new alliances such as breast cancer care with Alrijne hospital.
Research and valorisation
EUR 151.6 million project income for research and education (about 12% of revenue, computed)Research funded by grants and project income, with nearly 500 collaboration contracts with about 140 Leiden Bio Science Park partners and more than 1,400 research support and valorisation contracts in 2025. A new Research & Valorisation directorate bundles research support.
Education and training
Bachelor's and master's programmes in medicine and biomedical sciences for 3,500 academic students, plus nursing and allied-staff training through Zorgopleidingen LUMC; funded largely through state and university contributions.
Group companies and participations
Includes NecstGen (cell and gene therapy GMP facility, 100%), HollandPTC (proton therapy, 33%), Cardiologie Centrum Voorschoten (75%) and minority stakes such as GenomeScan; NecstGen and HollandPTC produced a EUR 21.2 million negative result on participations in 2025.
Strategic priorities
- Strategy "Door gezondheid gedreven" 2024-2028
- Three spearheads: regenerative medicine, population health and data-driven healthcare & AI, with the Leiden Bio Science Park as the anchor ecosystem.
- Digitaal Dichtbij AI and data programme
- AI in research, AI implementation and digital care such as LUMC@Home, MDO support and smart triage; Ambient Listening and an AI chatbot are to roll out in 2026.
- LUMC Connect reorganisation
- Four divisions were replaced by six clusters with new cluster boards from 1 January 2026, plus new Care and Research & Valorisation directorates.
- Appropriate, value-based care
- The transformation plan "Passende waardegedreven zorg" aims to cut nursing days, consultations, emergency visits and diagnostic tests; LUMC is making 4 million euros available to help teams work smarter.
- Financial discipline
- The 2026 budget targets a EUR 13.3 million result (1% of revenue), building to 1.5% in 2027.
Investments and deals
- Strategic Real Estate Plan to 2032
- Housing investments of over EUR 469 million to renew the hospital's buildings; 2026 spending focuses on the OR centre, education rooms, radiology and nursing floors.
- Electronic patient record replacement
- The HiX Standard Content EPD project started in 2025, costs EUR 21 million and runs to June 2026.
- Participations
- Additional capital went into HollandPTC, nTrans and RougeTx, and the stake in Cardiologie Centrum Voorschoten was raised from 60% to 75%; an EUR 8.7 million impairment was taken at NecstGen.
- Data platform
- A "dataplatform 2.0" is being explored with Erasmus MC and UMC Utrecht.
Challenges and risks
- Funding pressure
- Cabinet cuts to care income, a care budget that may no longer grow under the Integral Care Agreement, less education ministry money and harder-to-get research grants.
- Staff shortages and wage costs
- Personnel costs rose to EUR 740.0 million in 2025, and staffing growth is capped by the tight labour market.
- Loss-making participations
- NecstGen and HollandPTC produced a EUR 21.2 million negative result on participations, and NecstGen remains an important point of attention.
- IT security
- Downtime or a data leak from ransomware, hacks or DDoS is named among strategic risks, with cyberattacks flagged for 2026 onwards.
What leadership says
“Innovations from our laboratories and the Bio Science Park must be brought to our patients quickly”
“Hospitals have no choice but to do things smarter”
Where a supplier can help
- Clinical AI and documentation
- The Digitaal Dichtbij programme and the CFO's wish for an AI note-taker that writes into the patient record open the door to ambient listening and clinical documentation tools.
- EPD and data platform
- The HiX EPD replacement and the dataplatform 2.0 exploration need integration, data architecture and training partners.
- Productivity and process improvement
- Funding pressure and the 4 million euros set aside to work smarter favour process coaching, workflow and staffing tools.
- Construction and equipment
- The real estate plan to 2032, including the OR centre and radiology, creates demand for medical equipment, construction and fit-out suppliers.
- Cybersecurity
- IT security incidents are a named strategic risk, supporting security services and resilience tooling.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Leiden University Medical Center?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- LUMC Jaarverslag 2025 (annual report) with Jaarrekening 2025 (consolidated financial statements)
- Leiden University Medical Center (LUMC, legally Academisch Ziekenhuis Leiden) is a Dutch public-law university medical centre combining four core tasks: patient care, research, education and valorisation; it treats more than 1.3 million patients with complex conditions and had more than 11,000 staff at end-2025 (7,467 average FTE in the consolidated group).
- FY2025 consolidated operating revenue was EUR 1,286.3 million (2024: EUR 1,200.8 million); care revenue under the Health Insurance Act (Zvw) grew to EUR 689.1 million (2024: EUR 635.2 million). Group result was EUR 16.5 million (2024: EUR 26.6 million); the entity result of EUR 15.9 million beat budget, or EUR 11.7 million excluding one-offs.
- Balance sheet is solid: group equity EUR 405 million, solvency 39.5% and DSCR 7 against bank covenants of above 20% and at least 1.3; cash EUR 229.8 million; operating cash flow EUR 82 million; a EUR 50 million Deutsche Bank overdraft was not used.
- Strategy "Door gezondheid gedreven" (2024-2028) focuses on regenerative medicine, population health and data-driven healthcare & AI, with the Leiden Bio Science Park (LBSP) as the anchor ecosystem (LUMC has nearly 500 collaboration contracts with about 140 LBSP partners).
- Organisation reshaped by the LUMC Connect programme: four divisions replaced by six clusters with new cluster boards from 1 January 2026, plus a new Care directorate and a Research & Valorisation directorate.
- Big IT and building programmes: the HiX Standard Content electronic patient record (EUR 21 million, project to June 2026), the Digitaal Dichtbij AI/data programme (Ambient Listening and an AI chatbot to roll out in 2026, a "dataplatform 2.0" being explored with Erasmus MC and UMC Utrecht), and a long-term housing plan worth over EUR 469 million to 2032 (OR centre, radiology, nursing wards, education building).
- Weak spots are the participations: NecstGen (cell and gene therapy GMP facility, 100% owned) and HollandPTC (proton therapy, 33%) produced a EUR 21.2 million negative result on participations, and an EUR 8.7 million impairment was taken at NecstGen.
- 2026 budget targets a EUR 13.3 million result (1% of revenue), building to 1.5% in 2027; named pressures are cabinet cuts to care income, wage agreements, staff shortages and a possible fall in research income.
- Leadership change: Douwe Biesma stepped down as chair on 1 July 2025; cardiologist Martin Jan Schalij now chairs the Executive Board, with Ymke Fokma (CFO, from 1 April 2025), Henk-Jan Guchelaar (vice-chair, from 1 June 2025) and dean Marlies Reinders.
- "Als persoon Martin op de voorgrond? Dat voelt ongemakkelijk." - personal interview with Martin Schalij
- Personal interview with Martin Schalij, cardiologist and chair of LUMC's Executive Board, published by LUMC on 1 October 2025.
- Says that when he joined the board in 2021 care was "not good enough" and LUMC was almost placed under heightened supervision; care is now better, which lets LUMC integrate care and research.
- Priority: bring innovations from LUMC's labs and the Bio Science Park to patients quickly.
- Main message is future-proof care: the Netherlands spends 110 billion euros on care, demand is growing with ageing, so care must be organised smarter.
- The transformation plan "Passende waardegedreven zorg" aims to cut nursing days, consultations, emergency visits and diagnostic tests.
- Values nursing input: welcomes LUMC's new professor of Nursing and more nurses doing research; backed staff in the last collective-agreement talks.
- Still practises (outpatient clinic on Thursday mornings, cath lab on Fridays); signed on for two more years on 11 November 2024 instead of retiring.
- "Ik zie op alle afdelingen LUMC'ers die veel durven" - interview with Ymke Fokma
- Interview with Ymke Fokma, Executive Board member and CFO of LUMC since April 2025, published by LUMC on 12 November 2025.
- Financial context: universities get less money from the education ministry (OCW), research grants are harder to get since the Nationaal Groeifonds stopped, and the Integral Care Agreement (IZA) says the care budget may no longer grow, so hospitals must work smarter.
- LUMC is making 4 million euros available to help teams work smarter (project leaders, process coaches, freeing up staff).
- LUMC and Leiden University drew up an AI vision; a programme plan exists for Digitaal Dichtbij (AI and e-health); she wants an AI note-taker that writes the consultation report straight into the patient record.
- Regional digital projects she works on: MDO Support (multidisciplinary patient meetings across hospitals with data exchange) and SMART Triage with other hospitals and the ambulance service in Hollands Midden.
- Working on the construction of a new LUMC with Leiden University, the Bio Science Park and the municipality, with a staff sounding board.
- Sees the LUMC Connect programme as a new governance philosophy that gives employees responsibility at all levels, alongside an engagement survey and a leadership programme to retain talent.
Questions about Leiden University Medical Center
What is LUMC?
Leiden University Medical Center is a Dutch university medical centre combining patient care, research, education and valorisation, part of the Leiden Bio Science Park.
What is LUMC's revenue?
Consolidated operating revenue was EUR 1,286.3 million in 2025 (2024: EUR 1,200.8 million), with a group result of EUR 16.5 million.
How many employees does LUMC have?
More than 11,000 staff at end-2025, or 7,467 average FTE in the consolidated group.
Who leads LUMC?
Martin Jan Schalij chairs the Executive Board, with Henk-Jan Guchelaar (vice-chair), Ymke Fokma (CFO) and dean Marlies Reinders.
What is LUMC's strategy?
The 2024-2028 strategy focuses on regenerative medicine, population health and data-driven healthcare & AI, together with the Leiden Bio Science Park.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)